On June 26, Vertex Pharmaceuticals rose 3.26% in regular trading, trading at 498.61 USD/share, with turnover of $181 million.

On the news front, the company has seen a concentration of positive pipeline developments. On June 11, Vertex presented Phase 3 data at the European Hematology Association Congress showing Casgevy gene editing therapy delivered durable benefits in children aged 5 to 11 with severe sickle cell disease or transfusion-dependent beta thalassemia, with all treated patients remaining free of vaso-occlusive crises and achieving transfusion independence. Additionally, the U.S. FDA formally accepted the Biologics License Application for Povetacicept in IgA nephropathy under an accelerated approval pathway, marking a critical regulatory milestone.

Adding to sector tailwinds, the FDA recently issued new review regulations for gene editing therapies, allowing companies to reference prior knowledge to accelerate development. The broader biotech sector rallied in tandem, with Moderna up 11.26%, Gilead Sciences up 3.24%, and AbbVie up 2.35%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)